After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) ...

The LEAP-001 study evaluated the combination of Keytruda plus Lenvima for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair ...

The combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in the US, Canada and Australia – becoming the first drugs to go through a ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

Merck has previously tried to improve upon Keytruda with Eisai-partnered VEGFR inhibitor Lenvima in first-line PD-L1-positive NSCLC. In the phase 3 LEAP-007, the doublet led to a statistically ...

In the LEAP-002 study, Merck hoped to show that combining Keytruda with Lenvima would improve outcomes over two years' follow-up in patients with unresectable HCC. However, the duo was unable to ...

The Phase 3 LEAP-008 trial evaluating Keytruda plus Lenvima versus docetaxel for metastatic NSCLC progressed on or after platinum-containing chemotherapy and one prior anti-PD-1/-L1 immunotherapy ...

Prior to using these logos, familiarize yourself with Saint Louis University's logo guidelines. Saint Louis University logo marks are copyrighted. Use of these logos is restricted to the Saint Louis ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

In recent months, the Keytruda-AstraZeneca Lynparza combination and Keytruda with Eisai's Lenvima also failed separate trials as cancer treatments. Keytruda belongs to a class of medicines called ...

1 First presentation of results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating KEYTRUDA plus LENVIMA in combination with transarterial chemoembolization (TACE ...